SCHEMBL25835554

SCHEMBL25835554

CCCCCCCCCCCCCCCC(=O)NCCOCCNC(=O)CCOCCCl

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FAAH O00519 5/20 0.66
DNM1 Q05193 2/20 0.50
LPAR1 Q92633 2/20 0.49
LPAR2 Q9HBW0 2/20 0.49
ENPP2 Q13822 1/20 0.49
CASP2 P42575 1/20 0.49
CNR1 P21554 2/20 0.47
ALDH1A1 P00352 1/20 0.47
MAPT P10636 1/20 0.47
HPGD P15428 1/20 0.47
ALOX12 P18054 1/20 0.47
CNR2 P34972 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
NAAA Q02083 1/20 0.46
EPHX2 P34913 2/20 0.44
SELP P16109 1/20 0.44
GLP1R P43220 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26032911 0.98 FAAH (0.64) FAAHDNM1LPAR1LPAR2ENPP2
SCHEMBL25835512 0.97 FAAH (0.70) FAAHDNM1LPAR1LPAR2ENPP2
SCHEMBL26032894 0.95 FAAH (0.68) FAAHDNM1LPAR1LPAR2ENPP2
SCHEMBL25835403 0.92 LPAR1 (0.62) FAAHLPAR1LPAR2ENPP2CNR1
SCHEMBL25067300 0.91 FAAH (0.59) FAAHDNM1LPAR1LPAR2ENPP2
SCHEMBL31683866 0.89 FAAH (0.65) FAAHDNM1LPAR1LPAR2ENPP2
SCHEMBL28999762 0.89 FAAH (0.65) FAAHDNM1LPAR1LPAR2ENPP2
SCHEMBL20856919 0.89 FAAH (0.65) FAAHDNM1LPAR1LPAR2ENPP2
SCHEMBL25835398 0.89 CNR1 (0.67) FAAHLPAR1LPAR2ENPP2CNR1
SCHEMBL25835272 0.87 FAAH (0.46) FAAHCASP2CNR1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF Arrowhead Pharmaceuticals, Inc. 2023-08-24 US disclosed
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS Arrowhead Pharmaceuticals, Inc. 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS CPT1B, MUSK, MYLK2 FAAH 2901/4885DNM1 376/4885LPAR1 147/4885
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF MUSK, MYLK2, TNNC1 FAAH 4742/4885DNM1 695/4885LPAR1 1841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.